Europe Ophthalmic Drugs Market 2023-2030

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $1,500	133 Pages	Triton Market Research	April, 2024	TRTN18748636

Best Price Guarantee
Price	from $1,500
Length	133 Pages
Publisher	Triton Market Research
Published Date	April, 2024
SKU	TRTN18748636

Europe Ophthalmic Drugs Market 2023-2030

Market Outlook

Triton’s research report states that the European ophthalmic drugs market is anticipated to grow at a CAGR of 6.25% over the 2023-2030 forecast years. France, Italy, Spain, the United Kingdom, Poland, Germany, and the Rest of Europe are studied in this report.

Germany is experiencing positive growth in the ophthalmic market due to an increase in age-related macular degeneration, cataracts, and other eye disorders. There is a need to develop the technologies for ophthalmic drug therapies to meet its rising demand. The regulatory environment in Germany aims to track the innovations by new market entrants to deliver safe eye care drugs. An awareness regarding patient-free drug delivery is also a factor that contributes positively to the growth of the studied market.

On the other hand, in France, the ophthalmic drugs market is governed by the French National Agency for Medicines and Health Products Safety (ANSM). Their regulatory standards ensure the safe quality, efficacy, and delivery of products. The pharmaceutical companies in France receive huge investments to research and innovate these drugs. An increasing focus on patient-free health consultations and online prescriptions provides an accessible eye-care treatment facility, which influences the demand for ophthalmic drugs.

Competitive Outlook

The notable companies in the ophthalmic drugs market are Genentech Inc, Thea Pharma Inc, Pfizer Inc, Johnson & Johnson, Sun Pharmaceutical Industries Ltd, and Accutome Inc.

1. Europe Ophthalmic Drugs Market - Summary
2. Industry Outlook: 2.1. Technology Snapshot; 2.2. Impact Analysis On The Ophthalmic Drugs Market; 2.2.1. Covid-19 Impact On The Ophthalmic Drugs Market; 2.3. Porter’s Five Forces Analysis; 2.3.1. Threat Of New Entrants; 2.3.2. Threat Of Substitutes; 2.3.3. Bargaining Power Of Buyers; 2.3.4. Bargaining Power Of Suppliers; 2.3.5. Threat Of Competitive Rivalry; 2.4. Market Maturity Analysis; 2.5. Regulatory Framework; 2.6. Key Buying Impact Analysis; 2.7. Key Market Strategies; 2.7.1. Collaborations; 2.7.2. Product Launches; 2.7.3. Mergers & Acquisitions; 2.8. Market Drivers; 2.8.1. Aging Population Vulnerable To Eye Disorders; 2.8.2. Progress In Drug Delivery Technologies; 2.8.3. Escalating Incidence Of Ocular Diseases; 2.8.4. Reimbursement Policies By Healthcare Systems; 2.9. Market Challenges; 2.9.1. Challenging Timelines For Product Approval; 2.9.2. Adverse Effects Associated With Ophthalmic Drug Usage; 2.10. Market Opportunities; 2.10.1. Surge In Interest Regarding Topically Administered Ophthalmic Drugs; 2.10.2. Increase In Approvals For Innovative Ophthalmic Therapies; 2.11. Analyst Perspective
3. Europe Ophthalmic Drugs Market – By Type: 3.1. Prescription Drugs; 3.2. Over-the-counter Drugs
4. Europe Ophthalmic Drugs Market – By Condition: 4.1. Dry Eye; 4.2. Glaucoma; 4.3. Infection/Inflammation/Allergies; 4.4. Retinal Disorder; 4.4.1. Wet-age Related Macular Degeneration; 4.4.2. Dry-age Related Macular Degeneration; 4.4.3. Diabetic Retinopathy; 4.4.4. Other Retinal Disorders; 4.5. Other Conditions
5. Europe Ophthalmic Drugs Market – By Therapeutic Type: 5.1. Anti-glaucoma; 5.2. Anti-infection; 5.3. Anti-inflammatory; 5.4. Anti-allergy; 5.5. Other Therapeutic Types
6. Europe Ophthalmic Drugs Market – By Delivery Method: 6.1. Gels; 6.2. Eye Solutions & Suspensions; 6.3. Capsules & Tablets; 6.4. Eye Drops; 6.5. Ointments
7. Europe Ophthalmic Drugs Market – By Channel: 7.1. Hospital Pharmacies; 7.2. Drug Stores; 7.3. Online Pharmacies; 7.4. Other Channels
8. Europe Ophthalmic Drugs Market – Country Outlook: 8.1. United Kingdom; 8.1.1. United Kingdom Ophthalmic Drugs Market Forecast & Prospects; 8.2. Germany; 8.2.1. Germany Ophthalmic Drugs Market Forecast & Prospects; 8.3. France; 8.3.1. France Ophthalmic Drugs Market Forecast & Prospects; 8.4. Italy; 8.4.1. Italy Ophthalmic Drugs Market Forecast & Prospects; 8.5. Spain; 8.5.1. Spain Ophthalmic Drugs Market Forecast & Prospects; 8.6. Poland; 8.6.1. Poland Ophthalmic Drugs Market Forecast & Prospects; 8.7. Rest Of Europe; 8.7.1. Rest Of Europe Ophthalmic Drugs Market Forecast & Prospects
9. Competitive Landscape: 9.1. Abbvie Inc; 9.1.1. Overview; 9.1.2. Product Portfolio; 9.1.3. Key Strengths; 9.1.4. Key Challenges; 9.2. Bausch Health Companies Inc; 9.2.1. Overview; 9.2.2. Product Portfolio; 9.2.3. Key Strengths; 9.2.4. Key Challenges; 9.3. Johnson & Johnson; 9.3.1. Overview; 9.3.2. Product Portfolio; 9.3.3. Key Strengths; 9.3.4. Key Challenges; 9.4. Novartis Ag; 9.4.1. Overview; 9.4.2. Product Portfolio; 9.4.3. Key Strengths; 9.4.4. Key Challenges; 9.5. Regeneron Pharmaceuticals Inc; 9.5.1. Overview; 9.5.2. Product Portfolio; 9.5.3. Key Strengths; 9.5.4. Key Challenges; 9.6. Sun Pharmaceutical Industries Ltd; 9.6.1. Overview; 9.6.2. Product Portfolio; 9.6.3. Key Strengths; 9.6.4. Key Challenges; 9.7. Accutome Inc; 9.7.1. Overview; 9.7.2. Product Portfolio; 9.7.3. Key Strengths; 9.7.4. Key Challenges; 9.8. Genentech Inc; 9.8.1. Overview; 9.8.2. Product Portfolio; 9.8.3. Key Strengths; 9.8.4. Key Challenges; 9.9. Thea Pharma Inc; 9.9.1. Overview; 9.9.2. Product Portfolio; 9.9.3. Key Strengths; 9.9.4. Key Challenges; 9.10. Pfizer Inc; 9.10.1. Overview; 9.10.2. Product Portfolio; 9.10.3. Key Strengths; 9.10.4. Key Challenges
10. Research Methodology & Scope: 10.1. Research Scope & Deliverables; 10.2. Sources Of Data; 10.3. Research Methodology
Tables List: Table 1: Europe Ophthalmic Drugs Market, By Country Outlook, 2023-2030 (In $ Million); Table 2: Regulatory Framework; Table 3: List Of Collaborations; Table 4: List Of Product Launches; Table 5: List Of Mergers & Acquisitions; Table 6: Europe Ophthalmic Drugs Market, By Country Outlook, 2023-2030 (In $ Million); Table 7: Europe Ophthalmic Drugs Market, By Type, 2023-2030 (In $ Million); Table 8: Europe Ophthalmic Drugs Market, By Condition, 2023-2030 (In $ Million); Table 9: Europe Ophthalmic Drugs Market, By Retinal Disorder, 2023-2030 (In $ Million); Table 10: Europe Ophthalmic Drugs Market, By Therapeutic Type, 2023-2030 (In $ Million); Table 11: Europe Ophthalmic Drugs Market, By Delivery Method, 2023-2030 (In $ Million); Table 12: Europe Ophthalmic Drugs Market, By Channel, 2023-2030 (In $ Million)
Figures List: Figure 1: Technology Snapshot; Figure 2: Market Maturity Analysis; Figure 3: Europe Ophthalmic Drugs Market, By Type, 2022 & 2030 (In %); Figure 4: Europe Ophthalmic Drugs Market, By Prescription Drugs, 2023-2030 (In $ Million); Figure 5: Europe Ophthalmic Drugs Market, By Over-the-counter Drugs, 2023-2030 (In $ Million); Figure 6: Europe Ophthalmic Drugs Market, By Condition, 2022 & 2030 (In %); Figure 7: Europe Ophthalmic Drugs Market, By Dry Eye, 2023-2030 (In $ Million); Figure 8: Europe Ophthalmic Drugs Market, By Glaucoma, 2023-2030 (In $ Million); Figure 9: Europe Ophthalmic Drugs Market, By Infection/Inflammation/Allergies, 2023-2030 (In $ Million); Figure 10: Europe Ophthalmic Drugs Market, By Retinal Disorder, 2023-2030 (In $ Million); Figure 11: Europe Ophthalmic Drugs Market, By Retinal Disorder, 2022 & 2030 (In %); Figure 12: Europe Ophthalmic Drugs Market, By Wet Age-related Macular Degeneration, 2023-2030 (In $ Million); Figure 13: Europe Ophthalmic Drugs Market, By Dry Age-related Macular Degeneration, 2023-2030 (In $ Million); Figure 14: Europe Ophthalmic Drugs Market, By Diabetic Retinopathy, 2023-2030 (In $ Million); Figure 15: Europe Ophthalmic Drugs Market, By Other Retinal Disorders, 2023-2030 (In $ Million); Figure 16: Europe Ophthalmic Drugs Market, By Other Conditions, 2023-2030 (In $ Million); Figure 17: Europe Ophthalmic Drugs Market, By Therapeutic Type, 2022 & 2030 (In %); Figure 18: Europe Ophthalmic Drugs Market, By Anti-glaucoma, 2023-2030 (In $ Million); Figure 19: Europe Ophthalmic Drugs Market, By Anti-infection, 2023-2030 (In $ Million); Figure 20: Europe Ophthalmic Drugs Market, By Anti-inflammatory, 2023-2030 (In $ Million); Figure 21: Europe Ophthalmic Drugs Market, By Anti-allergy, 2023-2030 (In $ Million); Figure 22: Europe Ophthalmic Drugs Market, By Other Therapeutic Types, 2023-2030 (In $ Million); Figure 23: Europe Ophthalmic Drugs Market, By Delivery Method, 2022 & 2030 (In %); Figure 24: Europe Ophthalmic Drugs Market, By Gels, 2023-2030 (In $ Million); Figure 25: Europe Ophthalmic Drugs Market, By Eye Solutions & Suspensions, 2023-2030 (In $ Million); Figure 26: Europe Ophthalmic Drugs Market, By Capsules & Tablets, 2023-2030 (In $ Million); Figure 27: Europe Ophthalmic Drugs Market, By Eye Drops, 2023-2030 (In $ Million); Figure 28: Europe Ophthalmic Drugs Market, By Ointments, 2023-2030 (In $ Million); Figure 29: Europe Ophthalmic Drugs Market, By Channel, 2022 & 2030 (In %); Figure 30: Europe Ophthalmic Drugs Market, By Hospital Pharmacies, 2023-2030 (In $ Million); Figure 31: Europe Ophthalmic Drugs Market, By Drug Stores, 2023-2030 (In $ Million); Figure 32: Europe Ophthalmic Drugs Market, By Online Pharmacies, 2023-2030 (In $ Million); Figure 33: Europe Ophthalmic Drugs Market, By Other Channels, 2023-2030 (In $ Million); Figure 34: Europe Ophthalmic Drugs Market, By Country Outlook, 2022 & 2030 (In %); Figure 35: United Kingdom Ophthalmic Drugs Market, 2023-2030 (In $ Million); Figure 36: Germany Ophthalmic Drugs Market, 2023-2030 (In $ Million); Figure 37: France Ophthalmic Drugs Market, 2023-2030 (In $ Million); Figure 38: Italy Ophthalmic Drugs Market, 2023-2030 (In $ Million); Figure 39: Spain Ophthalmic Drugs Market, 2023-2030 (In $ Million); Figure 40: Poland Ophthalmic Drugs Market, 2023-2030 (In $ Million); Figure 41: Rest Of Europe Ophthalmic Drugs Market, 2023-2030 (In $ Million)